Use of tamoxifen for the treatment of nephrogenic systemic fibrosis

ENZ, PAULA A.; MUSSO, CARLOS GUIDO; FATO, C.; TORRE, A.; GALIMBERTI, R.; ALGRANATI, LUIS

Electron J Biomed

MJ Coma MD, PhD. Unidad de Investigación. Hospital General Yagüe

Año: 2009

Nephrogenic systemic fibrosis is (NSF) a rare entity which develops in patients with renal failure undergoing dialysis, and itsetiology is related to several factors such as the use of intravenous gadolinium, vascular surgeries, etc.Tamoxifen, is a selective modulator (competitive inhibition) of estrogen receptors, and it has antifibrotic properties which areused for treating retroperitoneal fibrosis, peritoneal sclerosis associated to peritoneal dialysis, desmoids tumors and in somecases of sclerodermia.In the present article, it is presented the hypothesis of a potential use of tamoxifen as a non immunosuppressant treatment forNSF in patients who have no contraindication for receiving it.